950210.KS
Prestige BioPharma Limited
KSC · Healthcare · Biotechnology · SG
KRW 6,470.00
−3.72%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 25.2B | 24.8B | 14.3B | 689.1M | 161.8M |
| Cost of Revenue | 32.4B | — | 38.3B | 1.2B | 33.9M |
| Gross Profit | (21.7B) | — | (24.0B) | (528.8M) | 127.9M |
| Operating Expenses | |||||
| R&D Expense | 23.2B | — | 19.1B | 23.4B | 40.9B |
| SG&A Expense | 40.1B | — | 23.6B | 45.4B | (53.4B) |
| General & Admin Expense | 55.4B | — | 3.2B | 17.2B | 28.7B |
| Selling & Marketing Expense | — | — | 7.7B | 12.7B | 10.9B |
| Other Expenses | 37.3B | 117.6B | 520.0M | (23.4B) | 24.9B |
| Total Operating Expenses | 85.5B | 117.6B | 43.3B | 45.4B | 12.4B |
| Cost and Expenses | 118.0B | 117.6B | 81.6B | 63.5B | 12.4B |
| Operating Income (EBIT) | (92.7B) | (92.8B) | (67.3B) | (62.8B) | 1.0B |
| Non-Operating | |||||
| Interest Income | 11.8B | — | 9.1B | 12.4B | 10.5B |
| Interest Expense | 13.4B | — | 7.6B | 7.4B | 950.8M |
| Net Interest Income | (1.6B) | — | 1.5B | 5.0B | 9.5B |
| Other Non-Op Income/Expense | (25.0B) | (25.0B) | 71.2B | 8.1B | (3.2B) |
| Non-Operating Income (excl Interest) | 1.0K | — | (78.8B) | (15.0B) | 2.2B |
| EBT (Pre-Tax Income) | (117.8B) | (117.8B) | 3.9B | (54.7B) | (2.1B) |
| Income Tax Expense | (150.1M) | (151.6M) | (248.2M) | 408.7M | 763.3M |
| Bottom Line | |||||
| Net Income | (96.7B) | (117.6B) | 22.3B | (32.9B) | 17.6B |
| Earnings from Cont. Ops | (118.7B) | (117.6B) | 4.2B | (55.1B) | (2.9B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (119.8B) | (117.6B) | 22.3B | (32.9B) | 17.6B |
| Per Share | |||||
| Basic EPS | (₩1,993) | (₩1,958) | ₩371 | (₩548) | ₩292 |
| Diluted EPS | (₩1,993) | (₩1,958) | ₩371 | (₩548) | ₩292 |
| Revenue Per Share | ₩420 | ₩413 | ₩238 | ₩11 | ₩3 |
| Shares | |||||
| Basic Shares Outstanding | 60.1M | 60.1M | 60.1M | 60.1M | 60.1M |
| Diluted Shares Outstanding | 60.1M | 60.1M | 60.1M | 60.1M | 60.1M |
| Profitability Metrics | |||||
| EBITDA | (69.0B) | (92.8B) | 33.3B | (31.0B) | 10.5B |
| D&A | 23.8B | — | 21.8B | 16.3B | 11.7B |
| EBIT | (92.7B) | (92.8B) | 11.5B | (47.3B) | (1.1B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026